The results from our successful analysis of more than 15,000 cancers from 152 tumor entities confirm the suggested utility of TTF-1 IHC for these applications but also highlight important pitfalls and emphasize the significance of combining TTF-1 analysis with Napsin-A and other immunohistochemical markers. This evidence concerns the gene NAPSA and neoplasm.